US 7,488,475 B2
	Antibody therapy of tumors
David S. F. Young, Toronto (Canada); Susan E. Hahn, Toronto (Canada); and Helen P. Findlay, Toronto (Canada)
Assigned to Arius Research, Inc., Toronto, Ontario (Canada)
Filed on Mar. 07, 2006, as Appl. No. 11/370,203.
Application 10/891866 is a division of application No. 10/348231.
Application 11/370203 is a continuation in part of application No. 10/743451, filed on Dec. 19, 2003, abandoned.
Application 10/743451 is a continuation of application No. 10/348231, filed on Jan. 21, 2003, granted, now 7,009,040, filed on Mar. 07, 2006.
Application 10/348231 is a continuation in part of application No. 10/891866, filed on Jul. 15, 2004, granted, now 7,186,808, filed on Mar. 06, 2007.
Prior Publication US 2006/0216234 A1, Sep. 28, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C12P 21/04 (2006.01); C12P 21/08 (2006.01); C07K 16/00 (2006.01)

U.S. Cl. 424—133.1  [424/141.1; 424/155.1; 424/181.1; 424/183.1; 435/69.6; 530/387.3; 530/388.1; 530/388.8; 530/391.7]

5 Claims

1. A method of treating human breast and prostate tumors in a mammal, wherein said human breast and prostate tumors express an antigen which specifically binds to the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as accession number PTA-4889, a humanized version thereof, a chimeric version thereof, or antigen binding fragments thereof, comprising administering to said mammal said monoclonal antibody, said humanized version thereof, said chimeric version thereof, or antigen binding fragments thereof in an amount effective to reduce said mammal's tumor burden.